| Tap a line for its trend | Currentlast close | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 2,527 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 95.7 | 95.7 | 25.2 | 32.9 | 27.4 | ||
| 81.8 | 81.8 | 96.4 | 51.3 | 43.8 | ||
| 2,513 | — | — | — | — | ||
| 471 | 471 | 397 | 319 | 268 | ||
| — | +18.6% | +24.4% | +19.2% | — | ||
| 145 | 145 | 119 | 91.1 | 74.7 | ||
| 30.9% | 30.9% | 29.8% | 28.5% | 27.9% | ||
| 99.7 | 99.7 | 79.1 | 64.5 | 54.5 | ||
| 70.1 | 70.1 | 54.7 | 46.4 | 36.9 | ||
| 14.9% | 14.9% | 13.8% | 14.5% | 13.8% | ||
| ₹147.02 | ₹147.02 | ₹114.62 | ₹97.23 | ₹77.43 | ||
| — | +28.3% | +17.9% | +25.6% | — | ||
| — | — | 94.5 | 89.8 | 69.6 | ||
| — | — | 94.5 | 89.8 | 69.6 | ||
From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 2,526.8 | |
| - Cash, Equiv & ST Investments | 27.4 | 32.9 | 25.2 | 95.7 | 95.7 | |
| + Total Debt | 43.8 | 51.3 | 96.4 | 81.8 | 81.8 | |
| Enterprise Value | — | — | — | — | 2,513.0 | |
| Revenue | 267.9 | 319.3 | 397.2 | 470.9 | 470.9 | |
| Growth %, YoY | — | +19.2 | +24.4 | +18.6 | — | |
| EBITDA | 74.7 | 91.1 | 118.5 | 145.3 | 145.3 | |
| Margin % | 27.88 | 28.52 | 29.84 | 30.86 | 30.86 | |
| EBIT | 54.5 | 64.5 | 79.1 | 99.7 | 99.7 | |
| Net Income | 36.9 | 46.4 | 54.7 | 70.1 | 70.1 | |
| Margin % | 13.78 | 14.52 | 13.76 | 14.89 | 14.89 | |
| EPS, Adj (current shares) | 77.43 | 97.23 | 114.62 | 147.02 | 147.02 | |
| Growth %, YoY | — | +25.6 | +17.9 | +28.3 | — | |
| Cash from Operations | 69.6 | 89.8 | 94.5 | — | — | |
| Free Cash Flow | 69.6 | 89.8 | 94.5 | — | — | |
Figures from the company's filings with NSE
In FY26 its consolidated net profit was ₹70.1 crore on revenue of ₹471 crore. Its debt-to-equity ratio was 0.24 on 31 March 2026.
No. Dr Agarwals Eye Hospital had borrowings of ₹81.8 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.24. Its cash and current investments were ₹95.8 crore, so it held net cash of ₹14 crore.
Dr Agarwals Eye Hospital's debt-to-equity ratio was 0.24 on 31 March 2026: borrowings of ₹81.8 crore against total equity of ₹346 crore.
Dr Agarwals Eye Hospital's net worth — shareholders' equity in its consolidated balance sheet — was ₹346 crore on 31 March 2026.
In FY26, Dr Agarwals Eye Hospital's return on equity (ROE) was 25.2% and its return on capital employed (ROCE) was 16.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 29.8% and ROCE 16.8%.
In FY26 (April 2025–March 2026), Dr Agarwals Eye Hospital's consolidated net profit was ₹70.1 crore, up 28.3% from ₹54.7 crore in FY25, on revenue from operations of ₹471 crore (up 18.6%). Over three years, from FY23, net profit was up 89.9%.
In FY26, Dr Agarwals Eye Hospital earned net profit of ₹70.1 crore on revenue of ₹471 crore, against ₹8 lakh on ₹53.7 crore for Lotus Eye Hospital and Institute. Dr Agarwals Eye Hospital's operating margin was 21.2% (Lotus Eye Hospital and Institute −0.7%) and its return on equity 25.2% (Lotus Eye Hospital and Institute 0.1%).
Dr Agarwals Eye Hospital's book value per share was ₹726.29 on 31 March 2026: shareholders' equity of ₹346 crore divided by the 47.68 lakh shares in issue.
Dr Agarwals Eye Hospital's basic earnings per share (EPS) were ₹147.02 in FY26, against ₹116.28 in FY25.
In 2026, Dr Agarwals Eye Hospital has declared one dividend: ₹4 with record date 2 September 2026.
On FY26 consolidated figures, against Lotus Eye Hospital and Institute: Dr Agarwals Eye Hospital's operating margin of 21.2% is the higher of the two (Lotus Eye Hospital and Institute −0.7%; peer average −0.7%); its return on equity of 25.2% is the higher of the two (Lotus Eye Hospital and Institute 0.1%; peer average 0.1%); its revenue growth over three years of 20.7% a year is the higher of the two (Lotus Eye Hospital and Institute 4.5% a year; peer average 4.5% a year).
From Dr Agarwals Eye Hospital's own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.